Metacrine
FXR and GLP-1 receptor agonist combination therapeutics for metabolic liver disease
- Sector
- Biotech
- Headquarters
- San Diego, CA
- Founded
- 2014
- Latest Form D
- $65M, Jun 2018
- Total capital
- $93.8M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $93.8M
- 3 Form D · last Jun 2018
- 100 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 9
- 31 pending · first 2019
- Rank in peer group#179 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$65M
- Private capital raisedForm D · SEC · 2nd filing$22M
- Private capital raisedForm D · SEC · 1st filing$6.8M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#179 · top 12%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Amir NashatDirectorNamed in SEC Form D filings
- Carol GallagherDirectorNamed in SEC Form D filings
- Jackie HernandezExecutive OfficerNamed in SEC Form D filings
- Kenneth SongExecutive Officer, DirectorNamed in SEC Form D filings
- Ken SongExecutive Officer, DirectorNamed in SEC Form D filings
- Kristina BurowDirectorNamed in SEC Form D filings
Show all 12 people
- Neil McDonnellExecutive Officer, DirectorNamed in SEC Form D filings
- Patricia MillicanExecutive OfficerNamed in SEC Form D filings
- Richard HeymanDirectorNamed in SEC Form D filings
- Robert AdelmanDirectorNamed in SEC Form D filings
- Ronald EvansDirectorNamed in SEC Form D filings
- Trisha MillicanExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 9 granted of 40- PendingHSD17B13 Inhibitors And Uses ThereofUSPTOApplication 18692305
- GrantedFarnesoid X Receptor Agonists And Uses ThereofUSPTOUS 11,773,094
- PendingFarnesoid X Receptor Agonists For The Treatment Of DiseaseUSPTOApplication 17836905
Show all 40 patent records
- HSD17B13 Inhibitors And Uses ThereofNov 7, 2024 · Application 18692305Pending
- Farnesoid X Receptor Agonists And Uses ThereofOct 3, 2023 · US 11,773,094Granted
- Farnesoid X Receptor Agonists For The Treatment Of DiseaseOct 13, 2022 · Application 17836905Pending
- Farnesoid X Receptor Agonists And Uses ThereofMar 24, 2022 · Application 17538394Pending
- Farnesoid X Receptor Agonists And Uses ThereofMar 17, 2022 · Application 17532618Pending
- Farnesoid X Receptor Agonists And Uses ThereofFeb 24, 2022 · Application 17276785Pending
- Farnesoid X Receptor Agonists And Uses ThereofFeb 24, 2022 · Application 17276787Pending
- Farnesoid X Receptor Agonists For The Treatment Of DiseaseFeb 17, 2022 · Application 17276766Pending
- Farnesoid X Receptor Agonists And Uses ThereofFeb 1, 2022 · US 11,236,071Granted
- Ssao Inhibitors And Uses ThereofJan 6, 2022 · Application 17287781Pending
- Farnesoid X Receptor Agonists And Uses ThereofJan 4, 2022 · US 11,214,538Granted
- Crystalline Forms Of A Farnesoid X Receptor AgonistNov 11, 2021 · Application 17276763Pending
- Farnesoid X Receptor Agonists And Uses ThereofSep 30, 2021 · Application 17152548Pending
- Farnesoid X Receptor Agonists And Uses ThereofAug 10, 2021 · US 11,084,817Granted
- Farnesoid X Receptor Agonists And Uses ThereofMar 30, 2021 · US 10,961,198Granted
- Farnesoid X Receptor Agonists And Uses ThereofFeb 23, 2021 · US 10,927,082Granted
- Farnesoid X Receptor Agonists And Uses ThereofJul 7, 2020 · US 10,703,712Granted
- Ssao Inhibitors And Uses ThereofJun 11, 2020 · Application 16791935Pending
- Farnesoid X Receptor Agonists And Uses ThereofApr 30, 2020 · Application 16494259Pending
- Farnesoid X Receptor Agonists And Uses ThereofApr 30, 2020 · Application 16494257Pending
- Farnesoid X Receptor Agonists And Uses ThereofApr 30, 2020 · Application 16494266Pending
- Farnesoid X Receptor Agonists And Uses ThereofApr 21, 2020 · US 10,626,081Granted
- Farnesoid X Receptor Agonists And Uses ThereofAug 13, 2019 · US 10,377,717Granted
- Farnesoid X Receptor Agonists And Uses ThereofFeb 28, 2019 · Application 15758710Pending
- Methods Of Treating Lipodystrophy Using FGF-1 CompoundsFeb 22, 2018 · Application 15727164Pending
- Farnesoid X Receptor Agonists For The Treatment Of DiseaseApplication PCTUS2021022788Pending
- Formulations Of A Farnesoid X Receptor AgonistApplication PCTUS2021022793Pending
- Farnesoid X Receptor Agonists For The Treatment Of DiseaseApplication 63032851Pending
- Ssao Inhibitors For The Treatment Of DiseaseApplication 63016722Pending
- Farnesoid X Receptor Agonists For The Treatment Of DiseaseApplication 62991301Pending
- Farnesoid X Receptor Agonists For The Treatment Of DiseaseApplication 63069667Pending
- HSD17B13 Inhibitors And Uses ThereofApplication 63085849Pending
- HSD17B13 Inhibitors And Uses ThereofApplication 63085843Pending
- Ssao Inhibitors For The Treatment Of DiseaseApplication PCTUS2021029473Pending
- HSD17B13 Inhibitors And Uses ThereofApplication 63325045Pending
- HSD17B13 Inhibitors And Uses ThereofApplication 63085846Pending
- Farnesoid X Receptor Agonists And Uses ThereofApplication PCTUS2019051603Pending
- Farnesoid X Receptor Agonists For The Treatment Of DiseaseApplication 63140735Pending
- HSD17B13 Inhibitors And Uses ThereofApplication 63244675Pending
- Farnesoid X Receptor Agonists For The Treatment Of DiseaseApplication PCTUS2019051604Pending
Related companies, and why
- D3 BioSimilar federal contract value in Biotech · null in contracts
- HOLOCLARA, INC.Similar federal contract value in Biotech · null in contracts
- REVIVO THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- BIOTHERYX, INC.Similar federal contract value in Biotech · null in contracts
- Bedrock Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- COGENTIS THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .